Background

Longer serum half-lives of perfluoroalkyl substances (PFAS) in humans compared to other species has been attributed to differences in the activity of organic anion transporters (OAT).

Methods

Among 56,175 adult participants in the community-based C8 Health Project, 23 subjects were taking the uricosuric OAT-inhibitor probenecid, and 36 subjects were taking the bile acid sequestrant cholestyramine. In regression models of log transformed serum PFAS, medication effects were estimated in terms of mean ratios, adjusting for age, gender, BMI, estimated glomerular filtration rate (eGFR) and water-district of residence.

Results

Probenecid was associated with modest, but not statistically significant increases in serum PFAS concentrations. In contrast, cholestyramine significantly lowered serum PFAS concentrations, notably for perfluorooctane sulfonic acid (PFOS).

Conclusions

The effectiveness of cholestyramine in a community setting supports the importance of gastrointestinal physiology for PFAS excretion kinetics, especially for PFOS. We did not find clear evidence that probenecid, an inhibitor of OAT, affects PFAS clearance.

中文翻译：

---

全氟烷基物质排泄：有机阴离子抑制和树脂结合药物在社区环境中的作用

背景

与其他物种相比，人类全氟烷基物质 (PFAS) 的血清半衰期更长，这归因于有机阴离子转运蛋白 (OAT) 活性的差异。

方法

在以社区为基础的 C8 健康项目的 56,175 名成年参与者中，23 名受试者服用促尿酸排泄 OAT 抑制剂丙磺舒，36 名受试者服用胆汁酸螯合剂消胆胺。在对数转换的血清 PFAS 的回归模型中，根据平均比率估计药物效应，调整年龄、性别、BMI、估计的肾小球滤过率 (eGFR) 和居住水区。

结果

Probenecid 与血清 PFAS 浓度的适度增加有关，但没有统计学意义。相比之下，消胆胺显着降低了血清 PFAS 浓度，尤其是全氟辛烷磺酸 (PFOS)。

结论

消胆胺在社区环境中的有效性支持胃肠生理学对 PFAS 排泄动力学的重要性，尤其是对 PFOS。我们没有发现明确的证据表明丙磺舒（一种 OAT 抑制剂）会影响 PFAS 的清除。